TRVI peer analysis
Trevi Therapeutics (TRVI) against its competitors: price, today's move, 1-year return and market value side by side.
TRVI and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | $20.47 | -0.58% | -9.98% | $3.55B |
| LQDA Liquidia | $41.84 | -7.15% | 80.34% | $4.03B |
| LXRX Lexicon Pharmaceuticals | $1.42 | -4.05% | 5.97% | $631.84M |
| RAPP Rapport Therapeutics | $25.10 | 0.20% | -6.62% | – |
| TENX Tenax Therapeutics | $1.79 | -3.76% | -76.04% | $66.99M |
| UPB Upstream Bio | $3.41 | 4.28% | -86.77% | – |
| VCRE Vicore Pharma | $9.80 | -3.92% | – | – |
| TRVI Trevi Therapeutics | $13.62 | 0.48% | 21.98% | $1.93B |
- TRVI's peers: ACAD (Acadia Pharmaceuticals), LQDA (Liquidia), LXRX (Lexicon Pharmaceuticals), RAPP (Rapport Therapeutics), TENX (Tenax Therapeutics), UPB (Upstream Bio), VCRE (Vicore Pharma).
Updated 2026-11-03 00:58 UTC